Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in catalytic arginine residues of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are common in glioma, acute myeloid leukemia, chondrosarcoma, cholangiocarcinoma, and angioimmunoblastic T-cell lymphoma. The mutant enzymes acquire a neomorphic activity that converts α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (D2HG), a rare metabolite. In cells and tissues expressing mutant IDH, D2HG concentrations are highly elevated. D2HG may act as an “oncometabolite” by inhibiting a class of α-KG–dependent enzymes involved in epigenetic regulation, collagen synthesis, and cell signaling. Knock-in mouse models of IDH1 mutations have shed light on these mechanisms and will provide valuable animal models for further investigation. Significance: Mutations in IDH1 and IDH2 promote the development of a number of malignancies. These active site mutations cause a gain-of-function leading to the accumulation of the rare metabolite D2HG. Mouse models of these mutations should provide insights into the mechanisms driving tumorigenesis and facilitate evaluation of new treatments. Cancer Discov; 3(7); 730–41. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“This can occur through multiple distinct mechanisms, including recurrent gain- or loss-of function mutations in enhancer of zeste 2 (EZH2), the primary methyltransferase responsible for this histone modification 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
In the citing paper
“EZH2 catalyses mono-, di- and tri-methylation of H3K27, which is linked to transcriptional silencing 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Cited by
Items 101–200 of 478
The metabolic cooperation between cells in solid cancer tumors
Icard, P., Kafara, P., Steyaert, J., Schwartz, L. H., & Lincet, H. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.06.002 · Cited by 87
Yamashita, A. S., Rosa, M. D. C., Borodovsky, A., Festuccia, W. T., Chan, T. A.-T., & Riggins, G. J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy146 · Cited by 77
Bhattacharyya, S., Pradhan, K., Campbell, N. R., Mazdo, J., Vasantkumar, A., Maqbool, S. B., Bhagat, T. D., Gupta, S., Suzuki, M., Yu, Y., et al. (2017) · Genome Research · doi:10.1101/gr.222794.117 · Cited by 84
“…gain-of-function mutations of IDH genes (either IDH1 or IDH2 ), which lead to production of an onco-metabolite (2-hydroxyglurate, 2-HG) that diminishes TET function through competitive blockade of oxoglutarate-dependent catalytic conversion of 5-mC to 5-hmC (Ward et al. 2010; Cairns and Mak 2013).”
Biology of IDH mutant cholangiocarcinoma
Wu, M., Shi, L., Merritt, J., Zhu, A. X., & Bardeesy, N. M. (2022) · Hepatology · doi:10.1002/hep.32424 · Cited by 74
“[51,52] (R)2HG is also produced in the metabolism of the neurotransmitter γ- hydroxybutyric acid by alcohol dehydrogenase iron- dependent isoform 1.[53] Under hypoxic or acidic conditions, which raise NADH levels, malate dehydrogenase 1/2 and lactate dehydrogenase A catalyze the production of (S)2HG by the promiscuous…”
BackgroundMoon, S. J., Dong, W., Stephanopoulos, G. N., & Sikes, H. D. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10184 · Cited by 80
PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
Sim, H., Galanis, E., & Khasraw, M. (2022) · Cancers · doi:10.3390/cancers14041003 · Cited by 71
“IDH mutations confer neomorphic activity that converts αketoglutarate to the oncometabolite 2-hydroxyglutarate [82].”
BackgroundUrban, D. J., Martinez, N. J., Davis, M. I., Brimacombe, K. R., Cheff, D. M., Lee, T. D., Henderson, M. J., Titus, S. A., Pragani, R., Rohde, J. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12630-x · Cited by 73
“F, Representative western blot from purified histones showing changes in H3K9me3 and H3K4me3 methylation levels in wild type IDH1 and mIDH1 expressing THP1 leukemic cells after 4 days of doxycycline following treatment with either vehicle, AG120 (1), or Novartis 530 (2) (n=2).”
BackgroundInfluentialAllosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity
Xie, X., Baird, D., Bowen, K. E., Čápka, V., Chen, J., Chenail, G., Cho, Y., Dooley, J., Farsidjani, A., Fortin, P. D., et al. (2017) · Structure · doi:10.1016/j.str.2016.12.017 · Cited by 70
Neitzel, C., Demuth, P., Wittmann, S., & Fahrer, J. (2020) · Cancers · doi:10.3390/cancers12071731 · Cited by 76
Lee, S. Y., Ju, M. K., Jeon, H. M., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1027453 · Cited by 71
Parsa, S., Ortega-Molina, A., Ying, H., Jiang, M., Teater, M. R., Wang, J., Zhao, C., Reznik, E., Pasion, J. P., Kuo, D. C., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0080-0 · Cited by 68
Porcellini, E., Laprovitera, N., Riefolo, M., Ravaioli, M., Garajova, I., & Ferracin, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.049 · Cited by 66
A prospective study of serum metabolites and glioma risk
Huang, J., Weinstein, S. J., Kitahara, C. M., Karoly, E. D., Sampson, J. N., & Albanes, D. (2017) · Oncotarget · doi:10.18632/oncotarget.19705 · Cited by 68
Chemotherapy for Bone Sarcoma in Adults
Wagner, M. J., Livingston, J. A., PATEL, S. R., & Benjamin, R. S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.009944 · Cited by 67
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Hvinden, I. C., Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100469 · Cited by 71
“I-Cit is oxidized to 2-OG, and NADP+ is reduced to NADPH.”
BackgroundInfluentialControl of the Antitumor Immune Response by Cancer Metabolism
Domblides, C., Lartigue, L., & Faustin, B. (2019) · Cells · doi:10.3390/cells8020104 · Cited by 68
“The affinity of mutant IDH1 to isocitrate decreases but its affinity for α-KG increases, favoring the neomorphic activity compared to normal activity [163].”
Chen, S., Fritchie, K., Wei, S., Ali, N. M., Curless, K. L., Shen, T., Brini, A. T., Latif, F., Sumathi, V. P., Siegal, G. P., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.05.015 · Cited by 63
“The pathogenesis by D-2hydroxygluturate has been under extensive study (17, 19-21).”
BackgroundTherapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma
Williams, M. J., Singleton, W., Lowis, S. P., Malik, K. T. A., & Kurian, K. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00045 · Cited by 65
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
Cuyàs, E., Fernández-Arroyo, S., Corominas-Faja, B., Rodríguez-Gallego, E., Bosch-Barrera, J., Martin-Castillo, B., De Llorens, R., Joven, J., & Menendez, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3733 · Cited by 58
“The discovery of cancer-specific mutations in metabolic enzymes has led to a renewed interest in cancer metabolism as a potential source of new targets for preventing and treating cancer [1-14].”
BackgroundEpigenetic therapies in acute myeloid leukemia: where to from here?
Fennell, K. A., Bell, C. C., & Dawson, M. A. (2019) · Blood · doi:10.1182/blood.2019003262 · Cited by 69
The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
Reiter–Brennan, C., Semmler, L., & Klein, A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.82642 · Cited by 63
“dox reactions, promoting tumorigenesis [17].”
Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma
Šamec, N., Zottel, A., Paska, A. V., & Jovčevska, I. (2020) · Molecules · doi:10.3390/molecules25030490 · Cited by 57
“The majority of IDH1 mutations consist of arginine to histidine mutation at NA 132 [61], after the which the enzyme becomes deficient but harbors new catalytic activity, namely the production of 2-hydroxyl-glutarate, which is associated with an altered chromatin state [62].”
BackgroundMutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
Grassian, A. R., Pagliarini, R. A., & Chiang, D. Y. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000050 · Cited by 58
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase
Ilic, N., Birsoy, K., Aguirre, A. J., Kory, N., Pacold, M. E., Singh, S., Moody, S. E., DeAngelo, J. D., Spardy, N. A., Freinkman, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617922114 · Cited by 51
“Discussion Mutations in metabolic genes, such in IDH1/2 (35), fumarate hydratase (36), succinate dehydrogenase (37, 38), and mitochondriaencoded genes (39), although relatively rare, are actively pursued for therapy because of their causal involvement in the tumors that carry those lesions.”
BackgroundLee, H., Lee, H., Jung, J. H., Shin, E. A., & Kim, S. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12496 · Cited by 56
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment
Speetjens, F. M., de Jong, Y., Gelderblom, H. A. J., & Bovée, J. V. M. G. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000300 · Cited by 58
“Mutations in IDH1 or IDH2 mostly result in a single arginine residue substitution and are mutually exclusive [18].”
BackgroundKoklesová, L., Samec, M., Líšková, A., Zhai, K., Büsselberg, D., Giordano, F. A., Kubatka, P., & Golubnitschaja, O. (2021) · The EPMA Journal · doi:10.1007/s13167-021-00237-2 · Cited by 53
Epigenetics in normal and malignant hematopoiesis: An overview and update 2017
Goyama, S., & Kitamura, T. (2017) · Cancer Science · doi:10.1111/cas.13168 · Cited by 58
Mitochondrial dysfunction, UPRmt signaling, and targeted therapy in metastasis tumor
Keerthiga, R., Pei, D., & Fu, A. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00696-0 · Cited by 54
Zeng, P., Lu, W., Tian, J., Qiao, S., Li, J., Glorieux, C., Wen, S., Zhang, H., Li, Y., & Huang, P. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01245-z · Cited by 55
“Mutations in IDH2 have been observed in several human cancers, especially in low-grade gliomas and AML patients [8, 9].”
BackgroundRoles of IDH1/2 and TET2 mutations in myeloid disorders
Inoue, S., Lemonnier, F., & Mak, T. W. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1973-7 · Cited by 57
Self-citationLevell, J. R., Caferro, T. R., Chenail, G., Dix, I., Dooley, J., Firestone, B., Fortin, P. D., Giraldes, J., Gould, T. A., Growney, J. D., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00334 · Cited by 52
Kaweme, N. M., Zhou, S., Changwe, G. J., & Zhou, F. (2020) · Biomarker Research · doi:10.1186/s40364-020-00242-z · Cited by 54
Grady, W. M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.02.006 · Cited by 54
Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies
Yu, X., Zhu, L., Wang, T., & Chen, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1037945 · Cited by 58
Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?
van Lith, S. A. M., Navis, A. C., Verrijp, K. N., Niclou, S. P., Bjerkvig, R., Wesseling, P., Tops, B. B. J., Molenaar, R. J., Noorden, C. J. F. V., & Leenders, W. P. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.004 · Cited by 57
Concepts in glioma immunotherapy
Platten, M., Bunse, L., Wick, W., & Bunse, T. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1874-x · Cited by 53
“1 3 results in a neomorphic enzyme function, leading to the production of the oncometabolite 2-hydroxyglutarate in excess amounts [37], which results in genetic instability via epigenetic modifications and hence tumorigenicity [38].”
BackgroundA Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit
Kopinja, J. E., Sevilla, R. S., Levitan, D. J., Dai, D. L., Vanko, A., Spooner, E., Ware, C., Forget, R., Hu, K., Kral, A. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14065-w · Cited by 53
It's complicated… m6A-dependent regulation of gene expression in cancer
Fitzsimmons, C. M., & Batista, P. J. (2018) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2018.09.010 · Cited by 55
“Mutations to IDH1 or IDH2 are present in approximately 80% of grade II-III gliomas (96–98), 50% of sporadic central and periosteal chondrosarcomas (99), 20–40% of angioimmunoblastic T cell lymphomas (AITL) (100), 10% to 20% of intrahepatic cholangiocarcinomas (101), and 12– 16% of AML patients (102).”
BackgroundRole of the mitochondrial stress response in human cancer progression
Wang, S., Chen, S., Tseng, L., & Lee, H. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220920558 · Cited by 54
“Moreover, IDH mutations might promote the development of a number of malignancies, such as glioma, myeloid neoplasia, chondrosarcoma, and cholangiocarcinoma.(69,70) SIRT3 (mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase, sirtuin-3) is responsible for protein deacetylation and regulates mitochondr…”
BackgroundCurrent and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review
Tomasik, B., Skrzypski, M. T., Bieńkowski, M., Dziadziuszko, R., & Jassem, J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-742 · Cited by 56
“Mutations in the IDH-1 and IDH-2 genes occur in majority of malignant gliomas (60–90%), 10–20% of acute myeloid leukemias, and up to approximately 1% of lung adenocarcinomas (154,155).”
Background5-Hydroxymethylcytosine: the many faces of the sixth base of mammalian DNA
Kriukienė, E., Tomkuvienė, M., & Klimašauskas, S. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00858d · Cited by 52
Lin, J., Lu, W., Caravella, J. A., Campbell, A. M., Diebold, R. B., Ericsson, A. M., Fritzen, E. L., Gustafson, G. R., Lancia, D. R., Shelekhin, T. E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00362 · Cited by 51
Epigenetic regulators and their impact on therapy in acute myeloid leukemia
Pastore, F., & Levine, R. L. (2016) · Haematologica · doi:10.3324/haematol.2015.140822 · Cited by 50
“Jumonji C (JmjC) domain-containing histone demethylases (JHDM) are 2- ketoglutarate-dependent dioxygenases leading to a demethylation of mono-/di- and trimethylated lysines on histones in the presence of iron and 2-ketoglutarate.52 JHDM are competitively inhibited by 2-HG,53,54 followed by impaired histone demethylati…”
BackgroundInfluentialFukumoto, K., Nguyen, T. B., Chiba, S., & Sakata‐Yanagimoto, M. (2017) · Cancer Science · doi:10.1111/cas.13393 · Cited by 51
“R132 IDH1 mutations were seen in myeloid malignancies.(34) Under physiologic conditions,”
BackgroundBiochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia
Fathi, A. T., Wander, S. A., Faramand, R. G., & Emadi, A. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.002 · Cited by 51
Metabolism of Preimplantation Embryo Development
Kaneko, K. J. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.04.010 · Cited by 56
IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy
Neal, A. J., Kwan, P., O'Brien, T. J., Buckland, M. E., Gonzales, M. F., & Morokoff, A. P. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.10.027 · Cited by 49
Enasidenib for the treatment of acute myeloid leukemia
Dugan, J. P., & Pollyea, D. A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1477585 · Cited by 50
Arginine deprivation and autophagic cell death in cancer
Szlosarek, P. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416560111 · Cited by 47
Madala, H. R., Punganuru, S. R., Arutla, V., Misra, S., Thomas, T., & Srivenugopal, K. S. (2018) · Cancers · doi:10.3390/cancers10020049 · Cited by 50
“IDH mutation derived D-2HG interferes with TET driven DNA demethylation, causing elevated 5-methylcytosine levels, resulting in the hypermethylat d signature on DNA, a characteristic feature of less differentiated cells [95].”
BackgroundMa, Q., Wang, J., Wang, Y., Hu, C., Mu, Q., Yu, M., Wang, L., Wang, D., Yang, M., Yin, X., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29395 · Cited by 51
“Furthermore, several studies suggest that IDH1 is an oncogene.(16) Over-expression of IDH1 results in glutamine reductive carboxylation in tumor cells under hypoxia.”
Unruh, D. J., Mirkov, S., Wray, B. D., Drumm, M. R., Lamano, J. B., Li, Y. D., Haider, Q. F., Javier, R., McCortney, K., Saratsis, A. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1222 · Cited by 48
“However, as such a cell model is inherently more artificial, it may not have the same biologic relevance as direct manipulation of actual patient-derived IDH1 and IDH1 glioma cells (46).”
BackgroundUSP29 coordinates MYC and HIF1α stabilization to promote tumor metabolism and progression
Tu, R., Kang, W., Yang, M., Wang, L., Bao, Q., Chen, Z., Dong, Y., Wang, J., Jiang, J., Liu, H., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02031-w · Cited by 45
Enasidenib and ivosidenib in AML
Martelli, M. P., Martino, G., Cardinali, V., Falini, B., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07024-x · Cited by 46
Poinsignon, V., Mercier, L., Nakabayashi, K., David, M. D., Lalli, A., Penard‐Lacronique, V., Quivoron, C., Saada, V., de Botton, S., Broutin, S., et al. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.030 · Cited by 45
Dinardo, C. D., Hochhaus, A., Frattini, M. G., Yee, K. W. L., Zander, T., Krämer, A., Chen, X., Ji, Y., Parikh, N. S., Choi, J., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03983-6 · Cited by 43
“The identification of oncogenic mutations in isocitrate dehydrogenase enzymes has revealed the interconnection of metabolomics, cellular signaling, and transcriptional regulation (Cairns and Mak 2013; Fujii et al. 2016).”
BackgroundGerometabolites: The pseudohypoxic aging side of cancer oncometabolites
MENENDEZ MENENDEZ, J., ALARCÓN, T., & Joven, J. (2014) · Cell Cycle · doi:10.4161/cc.28079 · Cited by 40
“Thus, proto-oncogenes and tumor suppressors possibly originated through evolution as components of metabolic regulation and, more importantly, so-called oncometabolites can directly impair the normal epigenetic regulation of cell differentiation and alter cell signaling to drive cellular transformation and oncogenesis…”
BackgroundGu, Y., Yang, R., Yang, Y., Zhao, Y., Wakeham, A. C., Li, W. Y., Tseng, A., Leca, J., Berger, T., Saunders, M. E., et al. (2020) · Blood · doi:10.1182/blood.2020007075 · Cited by 45
Self-citationMetabolic control of cancer cell stemness: Lessons from iPS cells
Menéndez, J. A. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1022697 · Cited by 40
“mutations in isocitrate dehydrogenase (IDH) generates the oncometabolite 2hydroxyglutarate (2HG).(124-130) Because IDH enzymes produce a-ketoglutarate, a cofactor for the TET family of DNA demethylases, neomorphic mutations of IDH that drive the aberrant neosynthesis of the TET inhibitor 2HG can be expected to mostly…”
BackgroundA metabolic perspective of Peto's paradox and cancer
Dang, C. V. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0223 · Cited by 40
Impact of DNA and RNA Methylation on Radiobiology and Cancer Progression
Chi, H., Tsai, C., Tsai, M.-M., & Lin, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020555 · Cited by 41
“Another report suggests that isocitrate dehydrogenase 1 or 2 (IDH1/2) mutant tumors account for ~20% of AML cases, causing aberrant metabolite D-2-hydroxyglutarate (D2HG) production [154], which acts as a competitive inhibitor of FTO through suppressing the activities of alpha-ketoglutarate-dependent enzymes.”
BackgroundRodrigues, D., Monteiro, M. S., Jerónimo, C., Henrique, R., Belo, L., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2016) · Translational research · doi:10.1016/j.trsl.2016.07.018 · Cited by 40
“Another interesting metabolite is 2-hydroxyglutarate (2HG), which is normally present at low levels in both its D-enantiomer and L-enantiomer in healthy individuals.(62) In several cancers, mutations in the gene encoding isocitrate dehydrogenase, which is responsible for the reduction of a-ketoglutarate to 2HG, may oc…”
Metabolic Regulation of Epithelial to Mesenchymal Transition: Implications for Endocrine Cancer
Bhattacharya, D., & Scimè, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00773 · Cited by 40
New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
Mhaidly, R., Krug, A., Gaulard, P., Lemonnier, F., Ricci, J., & Verhoeyen, E. (2020) · Oncogenesis · doi:10.1038/s41389-020-00259-x · Cited by 42
Bumes, E., Wirtz, F.-P., Fellner, C., Grosse, J., Hellwig, D., Oefner, P. J., Häckl, M., Linker, R. A., Proescholdt, M. A., Schmidt, N. O., et al. (2020) · Cancers · doi:10.3390/cancers12113406 · Cited by 40
Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy
Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 39
“Mammalian cells produce two chiral forms of the metabolite 2-hydroxyglutarate (2HG), R-2HG and S-2HG, which are typically kept at low levels in cells and body fl uids by speci fi c dehydrogenase enzymes converting them to a -KG (357).”
Falini, B., Sportoletti, P., Brunetti, L., & Martelli, M. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13409 · Cited by 40
“Moreover, increased levels of HIF factors in IDH-mutated neoplasms are likely to play a role in cancer development by activation of specific transcription regulatory networks, i.e., NFjB1, BRCA1, STAT3, and STAT1 (Cairns & Mak, 2013).”
BackgroundInfluentialIGFBP2 expression predicts IDH-mutant glioma patient survival
Huang, L. E., Cohen, A. L., Colman, H., Jensen, R. L., Fults, D. W., & Couldwell, W. T. (2016) · Oncotarget · doi:10.18632/oncotarget.13329 · Cited by 40
“Although IDH mutations are believed to drive glioma initiation by producing (R)2-HG, which results in DNA hypermethylation and metabolic reprograming [35-37], expression of mutant Idh1 in the mouse brain has yet to induce glioma formation despite robust production of (R)2-HG [11, 38].”
BackgroundMolecular Imaging of Metabolic Reprograming in Mutant IDH Cells
Viswanath, P., Chaumeil, M. M., & Ronen, S. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00060 · Cited by 39
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective
Ma, T., Zou, F., Pusch, S., Xu, Y., von Deimling, A., & Zha, X. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00159 · Cited by 35
New insights in the pathogenesis of T-cell lymphomas
Lemonnier, F., Gaulard, P., & de Leval, L. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000474 · Cited by 35
“(16, 21), and confer a neoenzymatic activity producing D-2 hydroxyglutarate (22).”
BackgroundAref, S., Areida, E.-S. K., Aaal, M. F. A., Adam, O. M., El-Ghonemy, M. S., ElBaiomy, M. A., & Abouzeid, T. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.05.009 · Cited by 35
Clinical development of cancer therapeutics that target metabolism
Clem, B. F., O’Neal, J., Klarer, A. C., Telang, S., & Chesney, J. A. (2015) · QJM · doi:10.1093/qjmed/hcv181 · Cited by 38
Chen, D., Xia, S., Wang, M., Lin, R., Li, Y., Mao, H. Z., Aguiar, M., Famulare, C. A., Shih, A. H., Brennan, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1040 · Cited by 36
“5), 10 mM MgCl 2 , 0.05% (w/v) bovine serum albumin) containing 15 μM NADPH (Sigma-Aldrich), 1.5 mM α -KG (Sigma-Aldrich).”
BackgroundInfluentialTargeting Immunometabolism in Glioblastoma
Mohan, A. A., Tomaszewski, W. H., Haskell-Mendoza, A. P., Hotchkiss, K. M., Singh, K., Reedy, J. L., Fecci, P. E., Sampson, J. H., & Khasraw, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.696402 · Cited by 35
Innovative Medicine: Basic Research and Development
Nakao, K., Minato, N., & Üemoto, S. (2015) · Springer eBooks · doi:10.1007/978-4-431-55651-0 · Cited by 10
Dong, L., & Neužil, J. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394625-6.00008-8 · Cited by 40
Upadhyay, V. A., Brunner, A. M., & Fathi, A. T. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.003 · Cited by 33
IDH1 deficiency attenuates gluconeogenesis in mouse liver by impairing amino acid utilization
Ye, J., Gu, Y., Zhang, F., Zhao, Y., Yuan, Y., Hao, Z., Sheng, Y., Li, W. Y., Wakeham, A. C., Cairns, R. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618605114 · Cited by 34
Self-citationEpigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
Park, J., & Turcan, Ş. (2019) · Cancers · doi:10.3390/cancers11101616 · Cited by 36
“IDH1/2 mutations have also been found in several types of cancers, covering enchondroma, chondrosarcoma, angioimmunoblastic T cell lymphoma (AITL), intrahepatic cholangiocarcinoma (ICC), and acute myeloid leukemia (AML) [27].”
BackgroundA pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
Kats, L. M., Vervoort, S. J., Cole, R., Rogers, A. J., Gregory, G. P., Vidacs, E., Li, J., Nagaraja, R., Yen, K. E., & Johnstone, R. W. (2017) · Leukemia · doi:10.1038/leu.2017.84 · Cited by 32
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
Paul, Y., Mondal, B., Patil, V. S., & Somasundaram, K. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0331-9 · Cited by 34
“IDH1 codes for a cytosolic protein that controls oxidative cellular damage [14, 15].”
Molecular Pathology of Bone Tumors
Lam, S. W., van IJzendoorn, D. G. P., Cleton-Jansen, A., Szuhai, K., & Bovée, J. V. M. G. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.11.002 · Cited by 33
Fujiwara, H., Tateishi, K., Misumi, K., Hayashi, A., Igarashi, K., Kato, H., Nakatsuka, T., Suzuki, N., Yamamoto, K., Kudo, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55211-w · Cited by 33
Polívka, J., Polívka, J., Rohan, V., Pešta, M., Repik, T., Pitule, P., & Topolčan, O. (2014) · BioMed Research International · doi:10.1155/2014/735659 · Cited by 36
“One of great importance among them is isocitrate dehydrogenase (IDH) [4, 5].”
BackgroundIDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway
Li, K., Ouyang, L., He, M., Luo, M., Cai, W., Tu, Y., Pi, R., & Liu, A. (2017) · Oncotarget · doi:10.18632/oncotarget.15868 · Cited by 34
“IDH1 dysfunction could induce energy metabolism disorders and cause the accumulation of ROS in cells [38, 39].”
BackgroundRohde, J. M., Surendra, K., Pragani, R., Liu, L., Fang, Y., Zhang, W., McIver, A. L., Zheng, H., Liu, Q., Davis, M. I., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00019 · Cited by 31
The Yin and Yang of cancer genes
Bashyam, M. D., Animireddy, S., Bala, P., Naz, A., & George, S. A. (2019) · Gene · doi:10.1016/j.gene.2019.04.025 · Cited by 36
Bai, X., Zhang, H., Zhou, Y., Nagaoka, K., Meng, J., Ji, C., Liu, D., Dong, X., Cao, K. Y., Mulla, J., et al. (2021) · Hepatology · doi:10.1002/hep.31486 · Cited by 31
“However, it has been identified that patients with glioma,(11) AML,(12) and CCA(13) as well as IDH mutations have better prognosis than those with WT IDH, albeit there are some controversial findings(36) that IDH mutations may target 2-OG-dependent enzymes in promoting malignant transformation and initiation.”
BackgroundMutant IDH1: An immunotherapeutic target in tumors
Schumacher, T., Bunse, L., Wick, W., & Platten, M. (2014) · OncoImmunology · doi:10.4161/2162402x.2014.974392 · Cited by 31
Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1
Kim, H.-J., Fei, X., Cho, S.-C., Choi, B. Y., Ahn, H., Lee, K., Seo, S., & Keum, Y. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.034 · Cited by 32
Dupuy, A., Lemonnier, F., Fataccioli, V., Martin‐Garcia, N., Robe, C., Pelletier, R., Poullot, E., Moktefi, A., Mokhtari, K., Rousselet, M. C., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.012 · Cited by 33
Butterfield, D. A., Favia, M., Spera, I., Campanella, A., Lanza, M., & Castegna, A. (2022) · Molecules · doi:10.3390/molecules27030951 · Cited by 31
“The impaired OXPHOS in AD could induce the accumulation of citrate and 2-OG, which are two potent epigenetic regulators [233,234].”
BackgroundFunctions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish
Shi, X. E., He, A. B.-L., Ma, A. C. H., Guo, Y., Chi, Y., Man, C. H., Zhang, W., Zhang, Y., Wen, Z., Cheng, T., et al. (2015) · Blood · doi:10.1182/blood-2014-09-601187 · Cited by 32
“In fact, increase in 2-HGper se, as inpatients with 2-HG aciduria, a condition in which serum 2-HG is increased because of homozygous loss-of-function mutations of 2-HG dehydrogenase enzymes, has not been known to cause leukemia.(11) The cooperative event leading to leukemogenesis is presently unclear and, in addition…”
BackgroundTissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas
Sim, H., Nejad, R., Zhang, W., Nassiri, F., Mason, W. P., Aldape, K., Zadeh, G. M., & Chen, E. X. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3205 · Cited by 31
“54 55 Mutations in IDH1/2 confer neomorphic activities that convert αKG to 2-hydroxyglutarate (2-HG) (20), with 56 preferential accumulation of the R- relative to the S- enantiomer of 2-HG (21).”
BackgroundMartin, K. C., Ma, C., & Yip, S. S. F. (2023) · Brain Sciences · doi:10.3390/brainsci13050817 · Cited by 31
Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics
Lee, S. C. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0449-ra · Cited by 30
Fortin, J., Chiang, M.-F., Meydan, C., Foox, J., Ramachandran, P., Leca, J., Lemonnier, F., Li, W. Y., Gams, M. S., Sakamoto, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208176120 · Cited by 29
Self-citationMolecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets
Oliveira, D. V. N. P., Zhang, S., Chen, X., Calvisi, D. F., & Andersen, J. B. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1292127 · Cited by 26
Metadata
- Authors
- Cairns, R. A., & Mak, T. W.
- Affiliations
- University Health Network (CA)
- Venue
- Cancer Discovery
- Published
- 2013-07-01
- Volume
- 3
- Issue
- 7
- Pages
- 730-741
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2111163869
- Cited by
- 452
- References
- 77
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 26 · 2023: 26 · 2022: 31 · 2021: 33 · 2020: 45 · 2019: 33 · 2018: 43 · 2017: 46 · 2016: 50 · 2015: 44 · 2014: 37 · 2013: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- IDH mutation, IDH1, IDH2, 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate, gain-of-function mutations, epigenetic regulation, collagen synthesis, knock-in mice, glioma, acute myeloid leukemia, cholangiocarcinoma, angioimmunoblastic T-cell lymphoma, chondrosarcoma, carcinogenesis
- MeSH terms
- Animals, Arginine, Glutarates, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasms, Gene Expression Regulation, Neoplastic, Epigenesis, Genetic, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.